Comparative effectiveness of myocardial cytoprotectors in chronic heart failure treatment

The study is focused on comparative effectiveness of myocardial cytoprotectors in chronic heart failure (CHF) treatment. In total, 120 patients with Functional Class (FC) II-III CHF were divided into two groups. For 60 days, Group I received mildronate, 1.0 g/d, Group II - preductal MV (trimetazidine), 60 mg/d, in addition to standard treatment. Control group received standard treatment only (n=20). Clinical examination was performed at Days 1, 14, and 60. Therapy effectiveness was assessed by subjective, objective, laboratory and instrumental data dynamics. In mildronate group, the parameters assessed had improved significantly, comparing to control and preductal MV groups.